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Abstract Mitochondrial diseases collectively represent one
of the most heterogeneous group of metabolic disorders.
Symptoms can manifest at any age, presenting with isolated
or multiple-organ involvement. Advances in next-generation
sequencing strategies have greatly enhanced the diagnosis of
patients with mitochondrial disease, particularly where a mi-
tochondrial aetiology is strongly suspected yet OXPHOS ac-
tivities in biopsied tissue samples appear normal. We used
whole exome sequencing (WES) to identify the molecular
basis of an early-onset mitochondrial syndrome—pathogenic
biallelic variants in the HTRA2 gene, encoding a
mitochondria-localised serine protease—in five subjects from
two unrelated families characterised by seizures, neutropenia,
hypotonia and cardio-respiratory problems. A unifying feature
in all affected children was 3-methylglutaconic aciduria (3-
MGA-uria), a common biochemical marker observed in some
patients with mitochondrial dysfunction. Although functional
studies of HTRA2 subjects’ fibroblasts and skeletal muscle
homogenates showed severely decreased levels of mutant
HTRA2 protein, the structural subunits and complexes of
the mitochondrial respiratory chain appeared normal. We did
detect a profound defect in OPA1 processing in HTRA2-
deficient fibroblasts, suggesting a role for HTRA2 in the reg-
ulation of mitochondrial dynamics and OPA1 proteolysis. In
addition, investigated subject fibroblasts were more suscepti-
ble to apoptotic insults. Our data support recent studies that
described important functions for HTRA2 in programmed cell
death and confirm that patients with genetically-unresolved 3-
MGA-uria should be screened by WES with pathogenic var-
iants in the HTRA2 gene prioritised for further analysis.
Introduction
Mitochondrial disorders can arise at any stage of life, often
presenting with a wide spectrum of clinical manifestations.
Genetically and phenotypically, mitochondrial diseases col-
lectively represent one of the most heterogeneous and
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common inherited groups of metabolic disorders. Due to the
challenges of assessing and definitively assigning genotype-
phenotype correlations in individuals, strategies to clinically
and molecularly characterise patients are continually develop-
ing to provide a comprehensive molecular portfolio of bona
fide variants causing mitochondrial disease. In recent years,
next-generation sequencing (NGS) technologies have proven
remarkably successful in identifying mutations in genes caus-
ing primary mitochondrial disorders, with more than 250
nuclear-encoded genes associated with mitochondrial syn-
dromes identified to date (Mayr et al 2015). However, given
the size of the human mitochondrial proteome—comprising
∼1300 gene products necessary to maintain mitochondrial
function—many pathogenic candidate genes remain
uncharacterised. This is highlighted by the many patients with
mitochondrial disease still requiring a diagnosis, where the
defective gene has not yet been established.
3-methylglutaconic aciduria (3-MGA-uria) is a biochemi-
cal marker of mitochondrial dysfunction in the presence of
suggestive clinical features (Wortmann et al 2013a, b).
Isolated 3-MGA-uria represents a clinically and genetically
heterogeneous group of metabolic disorders. Based on the
pathological mechanism, 3-MGA-uria syndromes have been
classified into two groups, ‘primary 3-MGA-uria’ associated
with defects in leucine catabolism and ‘secondary 3-MGA-
uria(s)’ that are not related to leucine degradation pathways
(Wortmann et al 2013a, b). The secondary 3-MGA-uria syn-
dromes may be distinguished into three different subtypes
based on the underlying pathomechanism: (1) defective phos-
pholipid synthesis and remodelling (SERAC1 defect or
MEGDEL syndrome, TAZ defect or Barth syndrome and
AGK defect or Sengers syndrome) (Barth et al 1983, 2004;
Kelley et al 1991; Mayr et al 2012; Wortmann et al 2012); (2)
mitochondrial membrane associated diseases (OPA3 defect or
Costeff syndrome, DNAJC19 defect or DCMA syndrome and
TMEM70 defect) (Anikster et al 2001; Davey et al 2006;
Cizkova et al 2008; Magner et al 2015) and (3) other mito-
chondrial proteins with unknown pathomechanism (CLPB
defect) (Kanabus et al 2015; Wortmann et al 2015)
Recently, Mandel and colleagues (Mandel et al 2016) iden-
tified the first case of recessive variants in the HTRA2 gene in
four infants from two unrelated families. HTRA2 encodes a
mitochondrial-localised serine protease and its absence has
been associated with 3-MGA-uria, infantile neurodegenera-
tion, abnormal mitochondria and increased sensitivity to apo-
ptosis (Mandel et al 2016). The HTRA2 defect represents a
novel cause of inborn error of metabolism with 3-MGA-uria
as a discriminative feature with an unknown pathomechanism.
Here we report two additional unrelated, consanguineous
families in which the affected children carried novel bi-
allelic pathogenic variants in the HTRA2 gene, leading to 3-
MGA-uria, seizures, hypotonia, neutropenia and cardio-
respiratory difficulties.
Patients and methods
Family 1 (subject 1)
The proband subject 1 (hereafter S1) was the second (male)
child of first cousin Pakistani parents who also have a healthy
daughter (Fig. 1a). He was born at term following an uncom-
plicated pregnancy. Hypoglycaemia on day 2 resolved once
feeding was established and he did not require any further
investigations. He was discharged aged 6 days but readmitted
after 1 week with poor feeding, apneas and excessive weight
loss. He was treated with anti-reflux medication and
discharged, but returned 2 weeks later with recurrent apneas
that progressed to central respiratory failure. On examination
at 3 weeks of age, he had bilateral cataracts, hypotonia, dys-
phagia and dystonic limb movements. Echocardiogram
showed poor cardiac contractility. The child had a respiratory
arrest at 2 months of age and could not be resuscitated. In the
family history, there are at least two other individuals who
died in early infancy with similar medical problems as S1
but the details are not available.
Investigations showed normal liver function tests, ammo-
nia 39 umol/L (normal range, 0–50 umol/L), CK 93 IU/L
(normal range, 0–229 IU/L), LDH 379 IU/L (normal range,
240–480 IU/L) and a normal plasma amino acid profile. The
urine organic acid profile showed increased excretion of 3-
methylglutaconic acid (levels not quantified) with normal ex-
cretion of 3-hydroxyisovalerate on three separate occasions.
The child had a persistent neutropenia (1.1×109; normal
range, 2.0–6.0 ×109). Urine reducing substances was negative
and GAL-1-PUT activity was normal. Lactate levels in the
serum (1.1 mmol/L; normal range, 0.7–2.1 mmol/L) and
CSF lactate (1.93 mmol/L; normal range, <2.0 mmol/L) were
normal. Cranial MRI at 3 weeks of age was normal with ap-
propriate myelination for a neonate and no abnormalities of
the basal ganglia were detected.
His male sibling was born a year later at term following a
normal pregnancy. He developed breathing difficulties at
3 days of age and similar feeding problems. He was fed via
a nasogastric tube initially, but discontinued as the respiratory
difficulties increased. He followed a similar clinical course to
his brother and the parents declined further investigations and
aggressive intensive care. He passed away at 3 weeks of age.
Family 2 (subject 2)
The proband, subject 2 (hereafter S2) was a male infant born
to first cousin Mexican parents at 41 weeks gestation follow-
ing a normal pregnancy. Mother had two healthy children
from a previous relationship (Fig. 1b). He was a large baby
weighing 4360 g at the 97.6 percentile line. Vaginal vertex
delivery was complicated by shoulder dystocia resulting in a
left Erb’s palsy and passage of fresh meconium, some of
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which was aspirated. Apgar scores were poor 11, 15, 210 and
blood gas analysis revealed a pH of 7.14. Respiratory effort
was weak, requiring intubation and artificial ventilation before
transfer to a neonatal intensive care unit. Extubation on day 3
was unsuccessful due to hypercarbia and he required contin-
ued ventilator support for central hypopnea. He was unable to
tolerate gastric feeds and received nutrition via a nasojejunal
tube. Seizures began on day 5 and continued despite anticon-
vulsant medication. Cranial MRI revealed a widespread im-
maturity of cortical development with elevated lactate and
lipid peaks on MRS. Skeletal muscle biopsy, performed at
2 weeks, showed muscle denervation and atrophy.
Echocardiogram demonstrated a large patent ductus
arteriosus. Supportive care was withdrawn after 3 months
when he continued to demonstrate respiratory insufficiency
and he died soon thereafter. Post mortem examination was
declined.Metabolic investigation revealed persistent elevation
of 3-methylglutaric and 3-methylglutaconic acids in urine.
Additional metabolic studies showing normal results included
plasma and urinary creatine and guanidinoacetate and plasma
thymidine. Diagnostic genetic studies showed no known del-
eterious variants in TAZ, TMEM70, POLG, SUCLA2,
SUCLG1 or in mtDNA.
The second affected infant in this family, subject 3 (S3), is
the sister of the index case who was born by vaginal delivery
at term weighing 3829 g with Apgar scores of 11, 15 and 810.
Although attempts at breast and bottle-feeding were noted to
be poor she was discharged from hospital on day 3, only to be
readmitted on day 7 with jaundice that required 2 days of
treatment. She was admitted again on day 27 with poor feed-
ing, weight loss and suspected seizures. Respiratory function
rapidly deteriorated on admission requiring intubation and
artificial ventilation for a period of 2 months, after which time
she was discharged, only to be readmitted 2 days later with
seizure-like activity and respiratory failure. Palliative therapy
was offered at home and she died 2 days later aged 4 months.
Fig. 1 Molecular genetics and
biochemical studies of HTRA2
variants. a, b Pedigrees of the two
affected families with variants in
the HTRA2 gene. The probands
S1 (family 1) and S2 (family 2)
are indicated by a red arrow and
filled symbols denote affected
individuals. c Amplification of
cDNA across HTRA2 exons 2–5
showed an aberrant splicing
pattern for HTRA2 RNA
transcripts in S1 as two abnormal
splice products were detected
compared to the wild type control
(C1). d, eWestern blot analysis of
HTRA2 levels in protein lysates
isolated from control (C1, C2)
and HTRA2 S1 skeletal muscle
and fibroblasts and from HTRA2
S2 mitochondrial muscle
homogenate. β-actin and SDHA
antibodies were used as loading
controls
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A post mortem was declined. Urine organic acid analysis
showed e leva t ed 3 -me thy lg lu t a r i c ac id and 3-
methylglutaconic acid.
The third affected child in this family, subject 4 (S4), was a
male born at 39 weeks gestation by elective caesarean section
for breech presentation. Apgar scores were good (7, 9) and the
immediate postnatal period uneventful. However, on day 2, he
developed profound bradycardia, tremors and clonus of both
lower extremities. Urine organic acid analysis confirmed 3-
methylglutaric and 3-methylglutaconic acids and he was rap-
idly transitioned to a palliative care pathway without further
investigation. He died at home at the age of 3 months. Post
mortem was not performed.
Whole exome sequencing analysis
Whole exome sequencing (WES) was undertaken for S1 and
S4 probands (Illumina HiSeq 2500 or Illumina HiSeq 2000)
using previously described methodologies and bioinformatics
filtering pipelines (Jones et al 2012; Bonnen et al 2013; Besse
et al 2015). Clinical WES was conducted on S4 at the Baylor
Miraca Genetics Laboratory. Putative pathogenic variants
were confirmed by Sanger sequencing of PCR-amplified
products using BigDye Terminator cycle sequencing chemis-
try (Applied Biosystems, ABI) on an ABI3130xl Genetic
Analyser. Sequence data were analysed using Mutation
Surveyor software v4.0.9 (SoftGenetics). Variant nomencla-
ture was annotated in reference to GenBank NM_013247.4
according to Human Genome Variation Society (HGVS)
guidelines.
cDNA studies
Total RNA was extracted from fibroblasts cultured from S1
using the ReliaPrep RNA Cell Miniprep System (Promega)
and reverse-transcribed to cDNA using the GoScript Reverse
Transcription System (Promega), according to the manufac-
turer’s guidelines. The cDNAwas then amplified across exons
2–5 using exonic primers (primer sequences and PCR condi-
tions available upon request) and PCR products were separat-
ed by agarose gel electrophoresis using standard conditions.
PCR products were directly sequenced as described above.
Cell culture conditions
Primary paediatric control and HTRA2 subjects’ fibroblasts
were cultured in Dulbecco’s modified Eagle’s medium
(Sigma) supplemented with 10 % fetal calf serum, 1 x non-
essential amino acids and 50 μg/ml uridine. Cell lines were
propagated at 37 °C in humidified 5 % CO2.
Western blot and blue native analysis
Western blot and blue native analysis was performed on avail-
able fibroblast and skeletal muscle protein samples from the
two affected subjects according to previously described meth-
odologies (Oláhová et al 2015; Oláhová, Hardy et al 2015)
and as indicated in Supplementary materials and methods.
Mitochondrial network analyses and confocal microscopy
Control (C1, C2) and subject (S1) fibroblasts were grown in
glass-bottomed wells (WillCo) to permit assessment of mito-
chondria and following incubation of cells at 37 °C for 45 mi-
nutes in the presence of the PicoGreen solution (Invitrogen) at
3 μl/ml, followed by a 15 minute incubation with 5nM
TMRM (Invitrogen). PicoGreen was used to visualise mito-
chondrial nucleoids and TMRM dye that is sequestered by
active mitochondria allowed the visualisation of the mito-
chondrial network. Cells were washed in standard growth me-
dia containing 5nM TMRM and images captured using a 63x
magnification oil immersion objective on an inverted point
scanning confocal microscope (Nikon A1R). Z-stack images
were processed and analysed by ImageJ. Images were
binarised allowing the automatic quantification of mitochon-
drial morphological characteristics shown as the aspect ratio
(AR) measuring mitochondrial length, perimeter and area.
Form factor (FF) was calculated by perimeter2/4pi∙area and
represents mitochondrial lengths and degree of branching.
Measurements were obtained from duplicate experiments
(each n = 10) and compared for differences between S1 and
two passage-matched controls (two-tailed unpaired Student’s
t-test).
Electron microscopy
Cultured fibroblasts were grown on Transwell® polyester
membrane cell culture inserts, fixed with 2 % glutaraldehyde
in 0.1 M cacodylate buffer and processed using the heavy
metal impregnation protocol as described previously
(Deerinck et al 2010). Briefly, the cells were immersed in
3 % potassium ferrocyanide + 2 % osmium tetroxide, follow-
ed by 0.1 % thiocarbohydrazide, then 2 % osmium tetroxide
and finally left overnight in 1 % uranyl acetate (with water
washes between each step). The next day the cells were im-
mersed in 0.6 % lead aspartate solution, dehydrated in graded
acetone and embedded in epoxy tab 812 hard resin. After
polymerisation, ultrathin sections were picked up on copper
grids for transmission electronmicroscopy (TEM) and the rest
of the resin block was used for serial block face scanning EM
imaging (SBF-SEM). Mitochondrial morphology was
analysed with a Zeiss SEM incorporating the 3View
GATAN® and a Philips CM100 TEM. Images were processed
in Digital Mircograph® and ImageJ.
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Apoptosis assay
Control (C1) and subject (S1) fibroblasts were treated with
either 0.3 μM staurosporine or vehicle alone 0.2 % dimethyl
sulfoxide (DMSO) for 8 hours. Apoptotic cells were analysed
in cultured fibroblasts using the APO-Direct Kit (BD
Biosciences) following manufacturer’s instructions. DNA
breaks were detected by labelling cells (n = 1 × 106) with the
terminal deoxynucleotidyl transferase conjugated to FITC.
Cells were exposed to excitation with 488 nm laser, following
FACS analysis performed on CANTO II flow cytometer. Total
DNAwas stained with propidium iodine.
Results
Whole exome sequencing analysis identifies HTRA2
variants
DNA from S1 (family 1) was subjected to WES, with bioin-
formatic filtering of the raw data undertaken in a step-wise
process to prioritise genes encoding proteins with a known
or predicted mitochondrial localisation harbouring rare,
recessively-inherited (compound heterozygous or homozy-
gous) variants. This facilitated the identification of pathogenic
HTRA2 variants. S1 was homozygous for a c.906 + 1G > C
splice site variant, which disrupts the consensus donor splice
site of intron 3 and leads to a complex, aberrant splicing pat-
tern of HTRA2 RNA transcripts (Fig. 1c and Supplementary
Fig. 1). Two abnormal splice products were observed follow-
ing RT-PCR: one shorter product resulting from the activation
of a cryptic splice site in exon 3 (removing nucleotides
r.781_906 from this transcript) and a longer product resulting
from complete retention of intron 3 (Fig. 1c and
Supplementary Fig. 1). The predicted effects of these splicing
patterns at the protein level are an in-frame deletion of 42
amino acids (p.Gly261_Asp302del) in the shorter transcript
and translational read-through of intron 3 resulting in the in-
clusion of 34 amino acids until a termination codon is encoun-
tered at position 35 (p.Asp302_Phe303ins*35) in the longer
transcript. There was no detectable evidence of a wild type
transcript using this method. Testing of parental samples con-
firmed carrier status. A molecular diagnosis was made in the
family whilst the mother was carrying her 6th pregnancy;
prenatal testing (CVB biopsy) at 12 weeks of gestation con-
firmed the absence of the c.[906 + 1G > C];[906 + 1G > C]
HTRA2 variant, and following a normal delivery this male
child continues to develop well.
In S4 (family 2), clinical WES identified a variant inHTRA2
c.728_730delinsCAT; p.Leu243_Pro244delinsProSer in an ap-
parently homozygous state. Parental samples were not available
for segregation analysis, but affected sibling, S2 (family 2), was
shown by Sanger sequencing to be homozygous for this variant
consistent with a shared clinical phenotype. Both residues,
p.Leu243 and p.Pro244, show evidence of being evolutionarily
constrained with PhyloP scores above 2.0, and are situated
within a highly conserved peptidase domain, whilst the muta-
tion in this family does not appear to give rise to a frameshift or
nonsense allele, thereby providing a trigger for nonsense-
mediated decay.
Deleterious variants in HTRA2 lead to complete loss
of HTRA2 protein
To determine the deleterious nature of the HTRA2 gene defect
on protein level, control (C1, C2) and subject fibroblasts (S1)
or skeletal muscle (S1, S2) samples were analysed by western
blotting. The steady-state levels of HTRA2 in subject fibro-
blasts (S1) and skeletal muscle (S1 and S2) were undetectable
when compared to age-matched controls (Fig. 1d and e),
strongly implying that both variants affect the translation, sta-
bility and/or the turnover of the HTRA2 protein.
OXPHOS steady-state levels and complex assembly
To characterise the impact of HTRA2 variants on the steady-
state levels of mitochondrial respiratory chain complex sub-
units, western blot analysis was performed on available fibro-
blast and skeletal muscle protein samples from the two affected
subjects. The loss of HTRA2 did not significantly affect the
steady-state levels of investigated OXPHOS subunits (Fig. 2a
and b). Protein lysates from S1 fibroblasts and skeletal muscle
revealed a marginal decrease in the levels of the complex I
subunit NDUFB8 (Fig. 2a). In addition, a slight decrease was
detected in the levels of the mitochondrial-encoded COXII
component of complex IV subunit in S1 skeletal muscle
(Fig. 2a). Investigation of mitochondrial extracts from skeletal
muscle tissue available from S2 revealed a slight decrease in the
steady-state levels of COXI subunit of complex IV (Fig. 2b).
The levels of other investigated complexes (I, II, III and V)
were normal in S2 skeletal muscle (Fig. 2b). In addition, normal
respiratory chain complex activities (complexes I-IV) were re-
ported following diagnostic screening in a muscle homogenate
from S2 (data not shown). The nuclear-encoded subunit of
complex II, SDHA, was used as a loading control.
One-dimensional blue native-PAGE (BN-PAGE) analysis
was performed to interrogate the assembly of mitochondrial
OXPHOS complexes in HTRA2 subjects. Due to limited
availability of muscle tissue from S1, the OXPHOS complex
assembly was determined only in fibroblasts. We observed a
minor defect in complex IVassembly in S1 fibroblasts and S2
muscle samples (Fig. 2c and d). The levels of fully assembled
complexes I, II, III and V were comparable to the control
fibroblasts and muscle tissue controls (C1, C2), respectively
(Fig. 2c and d). The nuclear-encoded subunit of complex II,
SDHA, was used as a loading control.
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Differential OPA1 proteolysis in HTRA2 subjects
Mitochondrial dynamics are regulated by a number of well-
characterised, inner mitochondrial membrane proteins that fa-
cilitate continuous fission and fusion of mitochondria. A key
player in this process is OPA1, a dynamin-related GTPase that
regulates mitochondrial fusion, cristae structure and apoptosis
(Olichon et al 2003; Frezza et al 2006). The balance between
the levels of long-OPA1 (L-OPA1) and short-OPA1 (S-OPA1)
cleavage products plays an important role in the fusion and
fission processes, and previous studies have reported a phys-
ical interaction between HTRA2 and OPA1 in mammals
(Kieper et al 2010). Here, we examined the levels of OPA1
in the HTRA2-deficient tissues and found differential proteo-
lytic processing of OPA1. In both, skin fibroblasts and skeletal
muscle derived from S1, we detected increased amounts of S-
OPA1 cleavage products (Fig. 3a). The increased proteolytic
processing of the L-OPA1 forms into S-OPA1 products in the
subject samples suggest that HTRA2 may affect mitochondri-
al fusion and OPA1 proteolysis.
Analysis of mitochondrial network and morphology
In order to further investigate the effect of HTRA2 variants on
mitochondrial dynamics, we assessed the mitochondrial
network and distribution of mitochondrial nucleoids in control
and S1 fibroblasts (Fig. 3b and c). The distribution and size of
the nucleoids appeared normal in subject fibroblasts when
compared to both controls (Fig. 3b and c). Similarly, mito-
chondria in subject fibroblasts displayed a well-connected tu-
bular network that was comparable to the control cell lines
(Fig. 3b and c).
Serial block face SEM of S1 fibroblasts did not reveal any
marked abnormalities in mitochondrial morphology and cris-
tae structure when compared to controls (Fig. 3d).
Transmission EM suggested that a subset of mitochondria in
S1 fibroblasts exhibited a decreased amount of inner mito-
chondrial membrane structures, however, these changes were
also observed to a similar level in both sets of control fibro-
blasts (Supplementary Fig. 2). These results indicate that, al-
though certain changes have been observed, the absence of
HTRA2 does not have an immense impact on mitochondrial
network and ultrastructure.
Investigation of apoptosis in HTRA2 subject fibroblasts
HTRA2 has been reported to play an important role in the
regulation of programmed cell death (Suzuki et al 2001;
Hegde et al 2002; Martins et al 2002; Kang et al 2013;
Mandel et al 2016). The release of HTRA2 into the cytosol
Fig. 2 Steady-state levels and
assembly of OXPHOS
complexes. a, b SDS-PAGE
(12 %) and immunoblot analysis
of steady-state levels of OXPHOS
complex subunits in protein
extracts (30ug) isolated from age-
matched control (C1, C2) and a
HTRA2 S1 fibroblasts (upper
panel) and skeletal muscle (lower
panel). bMitochondrial lysates
(40ug) from control and HTRA2
subject’s (S2) skeletal muscle
were used to analyse the levels of
OXPHOS complex subunits. In a
and b β-actin and SDHA served
as loading controls. c, d One-
dimensional BN-PAGE analysis
of the assembly of individual
OXPHOS complexes in DDM-
solubilised mitochondrial extracts
from control (C1, C2) andHTRA2
subject’s c fibroblasts (S1) and d
skeletal muscle (S2). Complex II
(SDHA) was used as a loading
control
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Fig. 3 Analysis of mitochondrial morphogenesis and apoptosis. a The
effects of loss of HTRA on OPA1 protein levels in control (C1, C2) and
subject (S1) fibroblasts and skeletal muscle were analysed by SDS-PAGE
(7 %) and immunoblotting against the mitochondrial fusion protein
OPA1. Differences in the OPA1 proteolytic cleavage pattern between
control and subject samples were detected, with increased levels of short
OPA1 cleavage products present in the HTRA2 subject (S1-S3). b The
panels on the left show representative images of TMRM staining in con-
trol C1 (upper), control C2 (middle) and subject S1 (lower) fibroblasts,
revealing a well-connected tubular mitochondrial network in subject 1
consistent with both controls. The panels on the right show representative
images of nucleoid staining by PicoGreen in control C1 (upper), control
C2 (middle) and subject S1 (lower) fibroblasts. Nucleoid size and distri-
bution in S1 is comparable to both controls. Scale bar = 10 μm. c
Quantitative analysis of mitochondrial network demonstrated a non-
significant difference in aspect ratio (left panel) and form factor (right
panel) of S1 compared to the controls. All data shown are represented
as mean ± SEM from two independent experiments. Statistical analysis
was performed using a two-tailed unpaired Student’s t-test, ns = not
significant. d Representative SBF-SEM images of mitochondria from
control (C1, C2) and HTRA2 subject (S1) fibroblasts showing morpho-
logically normal mitochondria with no obvious defects in cristae struc-
ture. Scale bar = 1 μm. e Quantitative analysis of the percentage of apo-
ptotic cells in population (n = 10 000) in control (C1) and subject (S1)
fibroblasts treated with or without 0.3 μM Staurosporine (ST) for 8 h.
Results are shown as mean STDEV (n = 2); paired Student’s t-test: C1 vs
S1 p = n.s., C1 vs C1 + ST p = 0.01; S1 vs S1 + ST p = 0.01 and C1 + ST
vs S1 + ST p = 0.03
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has been linked with both caspase-dependent and caspase-
independent activation of apoptosis (Vande Walle et al
2008). To investigate the effect of loss of HTRA2 on apopto-
sis, studied subject fibroblasts (S1) were treated in the pres-
ence of an apoptosis-inducing agent, staurosporine. Following
8 h treatment in the presence of 0.3 μM staurosporine, the
cellular morphology of both, control and subject fibroblasts
was altered compared to cells treated with vehicle alone
DMSO. Staurosporine exposure induced cellular shrinkage
and spherical cell bodies with thin stellate-like projections,
whilst cells treated with DMSO alone had a typical flattened
appearance (data not shown). Quantitative flow cytometry
analysis of apoptotic cells in the absence of staurosporine
did not show any significant increase in apoptosis in both
control and subject fibroblasts (Fig. 3e and Supplementary
Fig. 3). Conversely, staurosporine treatment increased the sen-
sitivity of HTRA2 deficient fibroblasts to apoptotic insults
(2.5 fold) compared to control cells (Fig. 3e and
Supplementary Fig. 3). These data suggest that in the absence
of HTRA2, cells are more susceptible to apoptosis, thus fur-
ther supporting the purported role of HTRA2 in the regulation
of apoptotic pathways.
Discussion
Using WES, we identified the molecular basis of increased 3-
MGA-uria in five individuals from two unrelated families pre-
senting with a variety of phenotypes including neutropenia,
hypotonia, dystonia, seizures, bilateral cataracts, central ap-
neas, feeding difficulties and cardio-respiratory symptoms.
The underlying genetic defect in both families was due to




In adults, variants in HTRA2 have been associated with de-
velopment of tremor and Parkinson’s disease (PD) (Unal
Gulsuner et al 2014; Tzoulis et al 2015). Despite the identifica-
tion of a large number of patients carrying PD HTRA2 variants,
the exact role of HTRA2 in PD still remains controversial
(Kruger et al 2011). Recent studies have identified the first case
of recessively-inherited pathogenic variants in theHTRA2 gene
[c.1211 G > A; p.(Arg404Gln) and c.1312_1316del;
p.(Ala438fs)] in four infants from two unrelated families
(Mandel et al 2016). In many aspects, the clinical features of
the individuals reported here very closely resemble those in the
recent publication (Mandel et al 2016). For example, affected
children presented with dysphagia and recurrent apnea, hypoto-
nia, bradycardia and seizures, whilst increased 3-MGA-uria was
a prominent feature in all four subjects.
HTRA2 encodes an ATP-independent serine protease that
resides in the mitochondrial intermembrane space, where it
acts in a protein quality control system. To date a number of
mitochondrial disease causing genes involved in mitochondri-
al protein quality control have been identified. Among these
are the heat shock protein/chaperonin CLPB (Kanabus et al
2015; Wortmann, Zietkiewicz et al 2015), the mitochondrial
matrix peptidase CLPP (Jenkinson et al 2013), subunits of the
mitochondrial matrix m-AAA protease AFG3L2 and SPG7
(Cagnoli et al 2010; Pfeffer et al 2014) and the conserved heat
shock protein 60 HSPD1 (Hansen et al 2007). Interestingly,
patients harbouring variants in CLPB protease are
characterised by increased 3-MGA-uria, neutropenia, epilep-
sy, cataracts and movement disorders, which are some of the
prominent features found in the individuals presented here
(Kanabus et al 2015; Wortmann et al 2015). It is possible that
the protease activity of HTRA2 could contribute to certain
post-transcriptional modifications of proteins that are directly
associated with inborn errors of metabolism with 3-MGA-uria
as discriminative feature.
The primary function of HTRA2 in mitochondria is to
maintain mitochondrial protein homeostasis. However,
studies have also reported that upon apoptotic stimuli,
HTRA2 is recruited to the cytosol where it activates apo-
ptotic caspases (Quiros et al 2015). Indeed, our results
suggest that complete loss of HTRA2 in the studied sub-
ject (S1) fibroblasts leads to increased sensitivity to apo-
ptosis (Fig. 3e and Supplementary Fig. 3). These findings
are in agreement with recent studies showing increased
apoptotic susceptibility in patients carrying recessive var-
iants in HTRA2 (Mandel et al 2016) and a mouse model
lacking neuronal HTRA2 (Kang et al 2013).
Human HTRA2 variants had a mild, or no effect, on the
steady state levels and assembly of mitochondrial respiratory
chain complexes in the fibroblasts and skeletal muscle ho-
mogenates studied here. Our findings show that loss of
HTRA2 influences the proteolytic processing of the mito-
chondrial dynamics regulator OPA1. The ubiquitously
expressed OPA1 is processed into L- and S-OPA1 protein
products, each of which have a distinct role in the control of
mitochondrial fission and fusion processes, cristae morpholo-
gy and apoptosis (MacVicar and Langer 2016). Mutated
HTRA2 caused differential proteolytic cleavage of OPA1
resulting in a marked increase of S-OPA1 forms that have
been associated with fragmented mitochondria. Despite the
increased amounts of S-OPA1 cleavage products detected in
HTRA2 subjects’ fibroblasts, we did not observe any signifi-
cant changes in the mitochondrial network or ultrastructure.
Although the exact role of HTRA2 in the regulation of mito-
chondrial morphology is not clear and it requires further in-
vestigation, it can be hypothesised that HTRA2 indirectly me-
diates OPA1 cleavage, initiating a different mode of mito-
chondrial fission-fusion represented by transient fusion that
is influenced by differentially expressed OPA1 levels (Liu
et al 2009). During transient fusion events mitochondria
128 J Inherit Metab Dis (2017) 40:121–130
rapidly exchange soluble contents whilst maintaining normal
mitochondrial network (Liu et al 2009)—a mode observed in
the fibroblasts derived from the individual carrying deleteri-
ous HTRA2 variants.
In conclusion, we report the identification of deleteri-
ous, biallelic variants in the HTRA2 gene encoding a
mitochondria-localised serine protease. HTRA2 variants
represent a novel and significant cause of rapidly
progressing, neonatal onset mitochondrial disease associ-
ated with 3-MGA-uria, hypotonia, dystonia, seizures and
cardio-respiratory difficulties. WES is proving to be a
powerful tool for investigating the genetic cause of mito-
chondrial syndromes in individuals with clinical evidence
of mitochondrial disease, but no other supportive bio-
chemical or genetic findings. Our findings confirm
HTRA2 to be an important candidate disease gene that
should either be directly screened in patients with in-
creased levels of 3-MGA, or variants in this gene identi-
fied by WES prioritised for further analysis.
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